Berkshire Sterile Manufacturing (BSM) provides the safest sterile drug products for clinical use and small-scale requirements through the use of modern technology, 100% isolator-based filling lines, and skilled staff. BSM offers sterile filling of syringes, vials (RTU and bulk), cartridges, custom containers, and lyophilized products. BSM also provides onsite analytical support and stability programs. BSM is a customer-focused, quality-driven contract manufacturer of sterile injectables

Our philosophy is to offer quality, and innovation to customers, utilizing new technologies to improve the sterility assurance and quality of the products while ensuring regulatory compliance

—Shawn Kinney, CEO

A global leader in stem cell therapy and research, dedicated to alleviating pain and suffering from autoimmune and degenerative diseases and help people enjoy longer and healthier lives. Based on innovations at the cutting edge of life sciences and regenerative medicine that was impossible to envision even a few years ago, BioXcellerator helps patients who suffer from a wide range of diseases, disorders, and injuries. The company is also focused on treating chronic traumatic encephalopathy (CTE) because many veterans and athletes who are diagnosed with post-traumatic stress disorder (PTSD) may actually be suffering from a physical brain injury that stem cell therapy can help treat

ClearLight Biotechnologies is a California-based company that empowers researchers to See More Biology™within the tissue microenvironment. The company provides CLARITY Tissue Clearing, 3D Immunohistochemistry (IHC), and Tru3D® Image Analysis services to pharmaceutical, biotechnology, and academic researchers. ClearLight works with larger undisturbed tissue volumes as compared to 2D thin section tissue slices.With the company’s tehnology researchers gain greater insights into the tissue’s subcellular structure when the third dimension is added. This technology has the potential to reduce the cost and failure rates of potential drug candidates during the costly drug development process

We create a hybrid tissue scaffold using CLARITY that allows us to see beyond the surface of the tissues and see deeper for spatial analysis

—Sharla White, PhD, Vice President of Research and Development

Eikonoklastes, a preclinical stage biopharmaceutical company, brings a novel approach to treating multiple solid tumors, including triple-negative breast cancer, ovarian cancer, and malignant melanoma. By developing novel immunotherapies that target tissue factors, a cell surface receptor prevalent in certain pathological cells, the company is making a breakthrough in cancer treatment. Eikonoklastes immunoconjugate technology was discovered by its scientific founder, Dr. Zhiwei Hu, who licensed it from the Ohio State University. He had realized the ubiquitous nature of tissue factor while working at Yale many years earlier. In his research, he identified tissue factor as a common biomarker and therapeutic target on various cancer cells and various types of solid tumors

Currently, we are focusing on the treatment of triple-negative breast cancer, ovarian cancer, and malignant melanoma, mainly because of its lowest survival rates

—Bruce Halpryn, CEO

Keystone Bio is a clinical-stage biopharmaceutical company. It is pioneering novel disease-modifying, precision, anti-bacterial bio- therapeutics/preventive along with companion diagnostics to target an important and largely unaddressed chronic bacterial infection and driver of systemic chronic inflammation that significantly contribute to multiple inflammatory disease states such as heart disease and dementia/Alzheimer’s disease. The company’s lead bio-therapeutic, KB-001 precision monoclonal antibody, disrupts the later stages of the major protein surface processing machinery. It also prevents the maturation of the unique subunit toxin —needed for its survival and the creation of its secreted outer membranes vesicles (OMVs), resulting in the bacteria shutting down it metabolic functions

Chronic inflammatory diseases have turned out to be a worldwide epidemic. KB-001 has equipped us with the ability to better help these patients and offer them a better life

Dr. Daniel Sindelar, DMD CEO and Dr. Peter Nara, D.V.M., Ph.D., FAAAS,CSO/V.P BD

Levitas, Inc. is redefining cellular processing with its next generation levitation technology. LevitasBio’s disruptive technology overcomes cellular processing’s current technological shortcoming by providing a label-free, simple, and gentle method of isolating specific cell populations. Its flagship product, the LeviCell platform, enables studies and beneficial uses of previously inaccessible, high-value primary samples and sensitive cell types regardless of the starting cell number, viability, or sensitivity to processing

We start right up from with native biological sample, and enable the researchers to process and analyze the sample in a way that doesn’t cause any damage, and doesn’t change the state of the sample itself

—Paul Steinberg, Chief Commercial Officer and Martin Pieprzyk, CEO

Nanotein Technologies offers protein-based solutions that allow biopharma companies to produce longer-lived and more clinically effective CAR-T cells in a larger quantity, and more quickly. Its tunable and flexible platform technology accelerates CAR-T expansion and increases the number of cells produced per treatment. By providing more control over the types of T-cell subsets that are produced in an expansion, this platform technology allows manufacturers to shift therapeutic profiles, enhancing the longevity and effectiveness of the final cell therapy product. Its novel cell activation and expansion reagent dramatically accelerates the development process and enables manufacturers to grow T-cell cultures with new cell population profiles in unusually large amounts

Our plug-and-play platform technology enables us to manipulate the cell surface of any cell with any antibody or combination of antibodies

—Curtis Hodge, PhD, Co-Founder and CEO

R3 Stem Cell has been at the forefront of performing regenerative therapies for the past decade. With over 16,000 regenerative therapies worldwide, they have never experienced a single significant adverse event. This is indeed a crowning achievement when compared to conventional treatment practices such as surgery and narcotic prescriptions. R3 Stem Cell’s therapies include PRP therapy, umbilical cord stem cell therapy, adipose cell therapy, and exosome therapy. The company is also among the most cost-effective regenerative therapy providers, thanks to its broad presence in the U.S. and abroad, spanning 45 centers

R3 Stem Cell’s growth trajectory entails partnering with practices that are looking to leverage regenerative medicine

David Greene, MD, MBA, Founder and CEO

Rakuten Medical is a global biotechnology company developing precision, cell-targeting investigational therapies on its IlluminoxTM platform, which, in pre-clinical studies, has shown to lead to rapid and selective cell killing and tumor necrosis

We at Rakuten Medical are focused on bringing an investigational treatment approach for our patients to provide them with one if the best options to fight cancer

—Carlos Garcia, Chief Technology Officer

Seneca Therapeutics is all set to move the needle in the cancer treatment space with its revolutionary cancer therapy. It is developing a pipeline of novel cancer agents utilizing Seneca Valley Virus-001 (SVV-001)—an oncolytic virus—that binds to the TEM8 (a single-pass cell surface protein predominantly expressed in tumor endothelium) receptor in solid tumors such as neuroendocrine tumors, breast cancer, and lung cancer. More importantly, SVV-001 converts cold tumors into hot tumors that enables T cells to recognize the tumor cells and destroy them

It is not a human virus and no pre-treatment neutralizing antibody has been detected in humans

—James Hussey, CEO